Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study

J Gastrointest Cancer. 2021 Sep;52(3):983-992. doi: 10.1007/s12029-020-00468-y.

Abstract

Purpose: Emerging evidences suggest that lymph node ratio (LNR), the number of metastatic lymph node (LN) to the total number of dissected lymph nodes (NDLN), may predict survival in multiple types of solid tumor. However, the prognostic role of LNR in adenocarcinoma of the esophagogastric junction (AEG) remains uninvestigated. The present study is intended to determine the prognostic value of LNR in the patients with Siewert type II AEG.

Methods: A total of 342 patients with Siewert type II AEG who underwent R0 resection were enrolled in this study. The optimal cutoff of LNR was stratified into tertiles using X-tile software. The log-rank test was used to evaluate the survival differences, and multivariate Cox regression analyses were performed to determine the independent prognostic variables.

Results: The optimal cutoff of LNR were classified as LNR = 0, LNR between 0.01 and 0.40, and LNR > 0.41. Patients with high LNR had a shorter 5- and 10-year disease-specific survival (DSS) rate (8.5%, 1.4%) compared with those with moderate LNR (20.4%, 4.9%) and low LNR (58.0%, 27.5%) (P < 0.001). Multivariate Cox regression analysis indicated that LNR was an independent factor for DSS after adjusting for confounding variables (P < 0.05). Furthermore, after stratification by NDLN between NDLN < 15 group and NDLN ≥ 15 group, the LNR remained a significant predictor for DSS (P < 0.05).

Conclusions: LNR is an independent predictor for DSS in patients with Siewert type II AEG regardless of NDLN. Patients with higher LNR have significantly shorter DSS.

Keywords: Adenocarcinoma of the esophagogastric junction; Lymph node ratio; Number of dissected lymph nodes; Prognosis.

MeSH terms

  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Esophageal Neoplasms / pathology*
  • Esophagogastric Junction / pathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Node Ratio / methods*
  • Male
  • Middle Aged
  • Neoplasm Staging / methods*
  • Prognosis
  • Stomach Neoplasms / pathology*